Table 1.

Number of subjects included at baseline and at follow-ups for each parameter measured

Biomarker	Months after baseline
	Baseline	6	12	18	24	36	48	60	72	84	96	108
Alzheimer’s disease
Amyloid-β1–42	95
Total tau	95
Phosphorylated tau	95
MMSE	95	93	84	1	76	8	2
ADAS-Cog	95	93	84	1	76	8	2
FDG-PET	49	45	41		32
Hippocampal volume	93	87	74		62
Healthy controls
Amyloid-β1–42	110
Total tau	110
Phosphorylated tau	110
MMSE	110	108	106		99	92	64	54	58	47	36	10
ADAS-Cog	110	108	106		99	92	64	54	58	47	36	11
FDG-PET	50	51	44		44	38	32	26	20	18	1
Hippocampal volume	107	106	100		86	77	47	28	20
Progressive MCI
Amyloid-β1–42	105
Total tau	105
Phosphorylated tau	105
MMSE	105	104	105	97	90	76	44	34	31	23	16	4
ADAS-Cog	105	104	105	97	90	76	44	34	31	23	16	5
FDG-PET	54	53	53	48	44	35	18	13	10	6	1
Hippocampal volume	104	98	98	90	77	61	35	17	7
Stable MCI
Amyloid-β1–42	68
Total tau	68
Phosphorylated tau	68
MMSE	68	68	68	66	63	53	24	20	20	15	14	1
ADAS-Cog	68	68	68	66	63	53	24	20	20	15	14	1
FDG-PET	34	34	34	34	30	23	12	9	10	5
Hippocampal volume	66	66	64	55	53	36	18	15	2